|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Genentech
gptkb:Foundation_Medicine
gptkb:Flatiron_Health
gptkb:Ventana_Medical_Systems
|
|
gptkbp:countryOfOperation
|
Worldwide
|
|
gptkbp:division
|
gptkb:Roche_Diagnostics
gptkb:Roche_Pharmaceuticals
|
|
gptkbp:focusArea
|
Neuroscience
Oncology
Immunology
Infectious diseases
Ophthalmology
|
|
gptkbp:founded
|
1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche (outside US)
|
|
gptkbp:industry
|
Pharmaceuticals
Diagnostics
|
|
gptkbp:ISIN
|
CH0012032048
|
|
gptkbp:keyPerson
|
gptkb:Severin_Schwan
gptkb:Christoph_Franz
|
|
gptkbp:languageOfService
|
gptkb:French
gptkb:German
English
|
|
gptkbp:legalForm
|
Aktiengesellschaft (AG)
|
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:notableProduct
|
gptkb:Actemra
gptkb:Avastin
gptkb:Herceptin
gptkb:MabThera
gptkb:Tamiflu
gptkb:Valium
gptkb:Xenical
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentCompany
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:products
|
Pharmaceutical drugs
Diagnostic tests
|
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Foundation_Medicine
gptkb:Chugai_Pharmaceutical
gptkb:Flatiron_Health
gptkb:Ventana_Medical_Systems
|
|
gptkbp:website
|
https://www.roche.com/
|
|
gptkbp:bfsParent
|
gptkb:REGEN-COV
|
|
gptkbp:bfsLayer
|
7
|